These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32737019)

  • 21. [Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories].
    Jelínek T; Kořístka M; Čermáková Z; Hájek R
    Klin Onkol; 2017; 30(1):13-19. PubMed ID: 28185460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
    Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
    Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients.
    Cottini F; Huang Y; Williams N; Bumma N; Khan AM; Chaudhry M; Devarakonda S; Efebera YA; Benson DM; Rosko AE
    Front Oncol; 2020; 10():575168. PubMed ID: 33659205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
    Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
    Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
    Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
    Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
    N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
    Shen F; Shen W
    Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 34. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
    Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
    Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
    Shah B; Gray J; Abraham I; Chang M
    J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
    J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 38. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.
    Lejeune M; Duray E; Peipp M; Clémenceau B; Baron F; Beguin Y; Caers J
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.
    Phipps C; Chen Y; Gopalakrishnan S; Tan D
    Ther Adv Hematol; 2015 Jun; 6(3):120-7. PubMed ID: 26137203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.